Trial results

24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine

NCT00975286 on ClinicalTrials.gov · last registry update 2016-10-11

Finished August 2011, after enrolling 446 people. Primary outcome, as filed: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24. lixisenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 1 time since then.

Status

COMPLETED

Phase

P3

Drug

lixisenatide

Soliqua, Adlyxin

Sponsor

Sanofi

Sponsor type

Industry

Enrollment

446

Started

2009-10

Primary completion

2011-08 actual

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24

Conditions studied

Type 2 Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the lixisenatide page for this molecule’s full trial and approval history.